This article has been corrected to note that the OncoTect 3Dx technology is slideless and the sample size for the study is 10,000 rather than the previously stated 100,000.

NEW YORK (GenomeWeb News) – IncellDx today said that is partnering with BioReference Laboratories to conduct a study comparing the firm's OncoTect 3Dx technology with other Pap smear systems.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.